{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:21:33Z","timestamp":1793316093442,"version":"4.5.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02211-y","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:19:50Z","timestamp":1773746390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Sepehr","family":"Dadfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasamin","family":"Eivazzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haniyeh","family":"Molavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Tavassoli Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariush","family":"Haghmorad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"2211_CR1","doi-asserted-by":"crossref","unstructured":"Peng S, Bao Y. A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. Annals Blood, 2022. 7.","DOI":"10.21037\/aob-21-3"},{"issue":"11","key":"2211_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","volume":"18","author":"A Tison","year":"2022","unstructured":"Tison A, et al. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol. 2022;18(11):641\u201356.","journal-title":"Nat Rev Rheumatol"},{"issue":"5256","key":"2211_CR3","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"8","key":"2211_CR4","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi FS, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci. 2003;100(8):4712\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"2211_CR5","doi-asserted-by":"crossref","unstructured":"Phan GQ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences, 2003. 100(14): pp. 8372\u20138377.","DOI":"10.1073\/pnas.1533209100"},{"issue":"8","key":"2211_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"26","key":"2211_CR7","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"2211_CR8","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.4110\/in.2022.22.e2","volume":"22","author":"JB Lee","year":"2022","unstructured":"Lee JB, Kim HR, Ha S-J. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 2022;22(1):e2.","journal-title":"Immune Netw"},{"issue":"19","key":"2211_CR9","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002;99(19):12293\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"2211_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med"},{"issue":"19","key":"2211_CR11","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, et al. Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167\u201375.","journal-title":"J Clin Oncol"},{"issue":"26","key":"2211_CR12","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, et al. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"2211_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, et al. Safety and tumor responses with lambrolizumab (anti\u2013PD-1) in melanoma. N Engl J Med. 2013;369(2):134\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"2211_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"2211_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"key":"2211_CR16","first-page":"12","volume":"171","author":"F Triebel","year":"1996","unstructured":"Triebel F. A novel lymphocyte activation gene closely related to CD4. J Exp Med. 1996;171:12.","journal-title":"J Exp Med"},{"issue":"4","key":"2211_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"C-T Huang","year":"2004","unstructured":"Huang C-T, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503\u201313.","journal-title":"Immunity"},{"issue":"2\u20133","key":"2211_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0165-2478(97)00170-3","volume":"61","author":"B Huard","year":"1998","unstructured":"Huard B, Tournier M, Triebel F. LAG-3 does not define a specific mode of natural killing in human. Immunol Lett. 1998;61(2\u20133):109\u201312.","journal-title":"Immunol Lett"},{"issue":"7","key":"2211_CR19","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/eji.200526090","volume":"35","author":"M Kisielow","year":"2005","unstructured":"Kisielow M, et al. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. 2005;35(7):2081\u20138.","journal-title":"Eur J Immunol"},{"issue":"8","key":"2211_CR20","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.4049\/jimmunol.168.8.3874","volume":"168","author":"S Andreae","year":"2002","unstructured":"Andreae S, et al. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol. 2002;168(8):3874\u201380.","journal-title":"J Immunol"},{"issue":"9","key":"2211_CR21","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/eji.1830250949","volume":"25","author":"B Huard","year":"1995","unstructured":"Huard B, et al. CD4\/major histocompatibility complex class II interaction analyzed with CD4-and lymphocyte activation gene\u20103 (LAG\u20103)\u2010Ig fusion proteins. Eur J Immunol. 1995;25(9):2718\u201321.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2211_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","volume":"115","author":"L Ma\u00e7on-Lema\u00eetre","year":"2005","unstructured":"Ma\u00e7on-Lema\u00eetre L, Triebel F. The negative regulatory function of the lymphocyte\u2010activation gene\u20103 co\u2010receptor (CD223) on human T cells. Immunology. 2005;115(2):170\u20138.","journal-title":"Immunology"},{"issue":"10","key":"2211_CR23","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","volume":"169","author":"CJ Workman","year":"2002","unstructured":"Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169(10):5392\u20135.","journal-title":"J Immunol"},{"issue":"1","key":"2211_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, et al. LAG 3 (CD 223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"key":"2211_CR25","doi-asserted-by":"crossref","unstructured":"He Y et al. TIM-3, a promising target for cancer immunotherapy. OncoTargets and therapy, 2018: pp. 7005\u20137009.","DOI":"10.2147\/OTT.S170385"},{"issue":"8","key":"2211_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molmed.2005.06.008","volume":"11","author":"JH Meyers","year":"2005","unstructured":"Meyers JH, et al. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med. 2005;11(8):362\u20139.","journal-title":"Trends Mol Med"},{"issue":"2","key":"2211_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.coi.2011.12.005","volume":"24","author":"AC Anderson","year":"2012","unstructured":"Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24(2):213\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"2211_CR28","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci. 2011;108(12):5009\u201314.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2211_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.20090397","volume":"207","author":"X Huang","year":"2010","unstructured":"Huang X, et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med. 2010;207(3):505\u201320.","journal-title":"J Exp Med"},{"issue":"8","key":"2211_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2217\/imt-2017-0024","volume":"9","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, et al. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9(8):681\u201392.","journal-title":"Immunotherapy"},{"issue":"1","key":"2211_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48\u201357.","journal-title":"Nat Immunol"},{"issue":"42","key":"2211_CR32","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci. 2009;106(42):17858\u201363.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"2211_CR33","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","volume":"188","author":"E Lozano","year":"2012","unstructured":"Lozano E, et al. The TIGIT\/CD226 axis regulates human T cell function. J Immunol. 2012;188(8):3869\u201375.","journal-title":"J Immunol"},{"issue":"11","key":"2211_CR34","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1172\/JCI81187","volume":"125","author":"S Kurtulus","year":"2015","unstructured":"Kurtulus S, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Investig. 2015;125(11):4053\u201362.","journal-title":"J Clin Investig"},{"issue":"7","key":"2211_CR35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723\u201332.","journal-title":"Nat Immunol"},{"issue":"11","key":"2211_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.it.2013.07.003","volume":"34","author":"S Ceeraz","year":"2013","unstructured":"Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34(11):556\u201363.","journal-title":"Trends Immunol"},{"issue":"5","key":"2211_CR37","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando J, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci. 2019;116(5):1692\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2211_CR38","first-page":"66","volume":"6","author":"JR Castellanos","year":"2017","unstructured":"Castellanos JR, et al. B7-H3 role in the immune landscape of cancer. Am J Clin experimental Immunol. 2017;6(4):66.","journal-title":"Am J Clin experimental Immunol"},{"key":"2211_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fimmu.2019.00617","volume":"10","author":"X Yu","year":"2019","unstructured":"Yu X, et al. BTLA\/HVEM signaling: milestones in research and role in chronic hepatitis B virus infection. Front Immunol. 2019;10:617.","journal-title":"Front Immunol"},{"issue":"1","key":"2211_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ni1144","volume":"6","author":"JR Sedy","year":"2005","unstructured":"Sedy JR, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005;6(1):90\u20138.","journal-title":"Nat Immunol"},{"issue":"4","key":"2211_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656\u201366.","journal-title":"Nat Med"},{"issue":"1","key":"2211_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-019-0045-x","volume":"4","author":"G Cao","year":"2019","unstructured":"Cao G, Xiao Z, Yin Z. Normalization cancer immunotherapy: blocking Siglec-15! Signal Transduct Target therapy. 2019;4(1):10.","journal-title":"Signal Transduct Target therapy"},{"key":"2211_CR43","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.coi.2023.102283","volume":"80","author":"KP Burke","year":"2023","unstructured":"Burke KP, et al. Immune checkpoint receptors in autoimmunity. Curr Opin Immunol. 2023;80:102283.","journal-title":"Curr Opin Immunol"},{"issue":"18","key":"2211_CR44","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.3390\/cancers13184573","volume":"13","author":"C Pisibon","year":"2021","unstructured":"Pisibon C, et al. Immune checkpoints in cancers: from signaling to the clinic. Cancers. 2021;13(18):4573.","journal-title":"Cancers"},{"issue":"12","key":"2211_CR45","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LS Walker","year":"2011","unstructured":"Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852\u201363.","journal-title":"Nat Rev Immunol"},{"issue":"5899","key":"2211_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, et al. CTLA-4 control over Foxp3\u2009+\u2009regulatory T cell function. Science. 2008;322(5899):271\u20135.","journal-title":"Science"},{"issue":"38","key":"2211_CR47","doi-asserted-by":"publisher","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, et al. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38):eabd2712.","journal-title":"Sci Adv"},{"issue":"3","key":"2211_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"230","key":"2211_CR49","doi-asserted-by":"publisher","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","volume":"5","author":"N Patsoukis","year":"2012","unstructured":"Patsoukis N, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5(230):ra46\u201346.","journal-title":"Sci Signal"},{"issue":"2","key":"2211_CR50","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459\u201365.","journal-title":"J Exp Med"},{"issue":"8","key":"2211_CR51","doi-asserted-by":"publisher","first-page":"a002436","DOI":"10.1101\/cshperspect.a002436","volume":"2","author":"JS Boomer","year":"2010","unstructured":"Boomer JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010;2(8):a002436.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"2211_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","volume":"229","author":"M Croft","year":"2009","unstructured":"Croft M, et al. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229(1):173\u201391.","journal-title":"Immunol Rev"},{"issue":"1","key":"2211_CR53","first-page":"49","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood J Am Soc Hematol. 2018;131(1):49\u201357.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6816","key":"2211_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35051113","volume":"409","author":"A Tafuri","year":"2001","unstructured":"Tafuri A, et al. ICOS is essential for effective T-helper-cell responses. Nature. 2001;409(6816):105\u20139.","journal-title":"Nature"},{"issue":"1","key":"2211_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","volume":"32","author":"AN Barclay","year":"2014","unstructured":"Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32(1):25\u201350.","journal-title":"Annu Rev Immunol"},{"key":"2211_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf K. Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. Eur J Cancer. 2017;76:100\u20139.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2211_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nri2303","volume":"8","author":"G Lemke","year":"2008","unstructured":"Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8(5):327\u201336.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2211_CR58","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nri3737","volume":"14","author":"MS Macauley","year":"2014","unstructured":"Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14(10):653\u201366.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2211_CR59","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/emmm.201100165","volume":"3","author":"K Karwacz","year":"2011","unstructured":"Karwacz K, et al. PD-L1 co\u2010stimulation contributes to ligand\u2010induced T cell receptor down\u2010modulation on CD8\u2009+\u2009T cells. EMBO Mol Med. 2011;3(10):581\u201392.","journal-title":"EMBO Mol Med"},{"key":"2211_CR60","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3389\/fimmu.2019.01242","volume":"10","author":"S Pesce","year":"2019","unstructured":"Pesce S, et al. PD\/1-PD-Ls checkpoint: insight on the potential role of NK cells. Front Immunol. 2019;10:1242.","journal-title":"Front Immunol"},{"key":"2211_CR61","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","volume":"10","author":"DO Khair","year":"2019","unstructured":"Khair DO, et al. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Front Immunol. 2019;10:453.","journal-title":"Front Immunol"},{"key":"2211_CR62","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","volume":"14","author":"L Chocarro","year":"2022","unstructured":"Chocarro L, et al. Clinical landscape of LAG-3-targeted therapy. Immunooncol Technol. 2022;14:100079.","journal-title":"Immunooncol Technol"},{"issue":"10","key":"2211_CR63","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.3390\/ijms22105282","volume":"22","author":"L Chocarro","year":"2021","unstructured":"Chocarro L, et al. Understanding LAG-3 signaling. Int J Mol Sci. 2021;22(10):5282.","journal-title":"Int J Mol Sci"},{"key":"2211_CR64","doi-asserted-by":"publisher","first-page":"1151748","DOI":"10.3389\/fimmu.2023.1151748","volume":"14","author":"B Garman","year":"2023","unstructured":"Garman B, et al. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands. Front Immunol. 2023;14:1151748.","journal-title":"Front Immunol"},{"issue":"2","key":"2211_CR65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cyto.a.22983","volume":"91","author":"AC Belkina","year":"2017","unstructured":"Belkina AC, Snyder-Cappione JE. OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets. Cytometry A. 2017;91(2):175\u20139.","journal-title":"Cytometry A"},{"key":"2211_CR66","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3389\/fimmu.2017.01215","volume":"8","author":"IS Okoye","year":"2017","unstructured":"Okoye IS, et al. Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol. 2017;8:1215.","journal-title":"Front Immunol"},{"issue":"10","key":"2211_CR67","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/CM9.0000000000001981","volume":"135","author":"L Zhao","year":"2022","unstructured":"Zhao L, et al. Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications. Chin Med J (Engl). 2022;135(10):1203\u201312.","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"2211_CR68","doi-asserted-by":"publisher","first-page":"e109080","DOI":"10.1371\/journal.pone.0109080","volume":"9","author":"NM Durham","year":"2014","unstructured":"Durham NM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS ONE. 2014;9(11):e109080.","journal-title":"PLoS ONE"},{"issue":"49","key":"2211_CR69","doi-asserted-by":"publisher","first-page":"81341","DOI":"10.18632\/oncotarget.13228","volume":"7","author":"AK Mishra","year":"2016","unstructured":"Mishra AK, et al. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8\u2009+\u2009T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. Oncotarget. 2016;7(49):81341\u201356.","journal-title":"Oncotarget"},{"key":"2211_CR70","doi-asserted-by":"crossref","unstructured":"Maruhashi T et al. LAG-3: from molecular functions to clinical applications. J Immunother Cancer, 2020. 8(2).","DOI":"10.1136\/jitc-2020-001014"},{"issue":"5","key":"2211_CR71","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3892\/ol.2020.12070","volume":"20","author":"C Shan","year":"2020","unstructured":"Shan C, Li X, Zhang J. Progress of immune checkpoint LAG-3 in immunotherapy. Oncol Lett. 2020;20(5):207.","journal-title":"Oncol Lett"},{"issue":"12","key":"2211_CR72","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/17460441.2022.2148652","volume":"17","author":"M Perez-Santos","year":"2022","unstructured":"Perez-Santos M, et al. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov. 2022;17(12):1341\u201355.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"2211_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/imr.13270","volume":"318","author":"AC Villani","year":"2023","unstructured":"Villani AC. The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients. Immunol Rev. 2023;318(1):4\u201310.","journal-title":"Immunol Rev"},{"issue":"1","key":"2211_CR74","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1111\/imr.70002","volume":"330","author":"VC Luca","year":"2025","unstructured":"Luca VC. LAG Time in the Era of Immunotherapy-New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene-3. Immunol Rev. 2025;330(1):e70002.","journal-title":"Immunol Rev"},{"issue":"9","key":"2211_CR75","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415\u201322.","journal-title":"Nat Immunol"},{"issue":"1","key":"2211_CR76","doi-asserted-by":"publisher","first-page":"ltab025","DOI":"10.1093\/immadv\/ltab025","volume":"2","author":"SEA Burnell","year":"2022","unstructured":"Burnell SEA, et al. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunother Adv. 2022;2(1):ltab025.","journal-title":"Immunother Adv"},{"issue":"1","key":"2211_CR77","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1038\/s41467-023-41756-y","volume":"14","author":"J Chongsaritsinsuk","year":"2023","unstructured":"Chongsaritsinsuk J, et al. Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE. Nat Commun. 2023;14(1):6169.","journal-title":"Nat Commun"},{"issue":"1","key":"2211_CR78","doi-asserted-by":"publisher","first-page":"17512","DOI":"10.1038\/s41598-018-35754-0","volume":"8","author":"AK Gandhi","year":"2018","unstructured":"Gandhi AK, et al. High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3. Sci Rep. 2018;8(1):17512.","journal-title":"Sci Rep"},{"issue":"1","key":"2211_CR79","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","volume":"235","author":"GJ Freeman","year":"2010","unstructured":"Freeman GJ, et al. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010;235(1):172\u201389.","journal-title":"Immunol Rev"},{"issue":"10","key":"2211_CR80","doi-asserted-by":"publisher","first-page":"e0140694","DOI":"10.1371\/journal.pone.0140694","volume":"10","author":"B Tomkowicz","year":"2015","unstructured":"Tomkowicz B, et al. TIM-3 Suppresses Anti-CD3\/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS ONE. 2015;10(10):e0140694.","journal-title":"PLoS ONE"},{"issue":"10","key":"2211_CR81","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1073\/pnas.1712107115","volume":"115","author":"L Avery","year":"2018","unstructured":"Avery L, et al. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc Natl Acad Sci U S A. 2018;115(10):2455\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2211_CR82","doi-asserted-by":"crossref","unstructured":"Pagliano O et al. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J Clin Invest, 2022. 132(9).","DOI":"10.1172\/JCI152864"},{"issue":"19","key":"2211_CR83","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/MCB.05297-11","volume":"31","author":"J Lee","year":"2011","unstructured":"Lee J, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31(19):3963\u201374.","journal-title":"Mol Cell Biol"},{"issue":"69","key":"2211_CR84","doi-asserted-by":"publisher","first-page":"eabm0631","DOI":"10.1126\/sciimmunol.abm0631","volume":"7","author":"R Tang","year":"2022","unstructured":"Tang R, et al. Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Sci Immunol. 2022;7(69):eabm0631.","journal-title":"Sci Immunol"},{"issue":"5","key":"2211_CR85","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41419-023-05848-3","volume":"14","author":"M Mishra","year":"2023","unstructured":"Mishra M, et al. TIM-3 increases the abundance of type-2 dendritic cells during Leishmania donovani infection by enhancing IL-10 production via STAT3. Cell Death Dis. 2023;14(5):331.","journal-title":"Cell Death Dis"},{"key":"2211_CR86","doi-asserted-by":"crossref","unstructured":"Sakuma M et al. TIM-3 Expression on Dendritic Cells in Colorectal Cancer. Cancers (Basel), 2024. 16(10).","DOI":"10.3390\/cancers16101888"},{"issue":"5","key":"2211_CR87","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","volume":"2","author":"IP da Silva","year":"2014","unstructured":"da Silva IP, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410\u201322.","journal-title":"Cancer Immunol Res"},{"key":"2211_CR88","first-page":"167","volume":"11","author":"M Khan","year":"2020","unstructured":"Khan M, Arooj S, Wang H. NK Cell-Based Immune Checkp Inhib Front Immunol. 2020;11:167.","journal-title":"NK Cell-Based Immune Checkp Inhib Front Immunol"},{"issue":"12","key":"2211_CR89","doi-asserted-by":"publisher","first-page":"e946365","DOI":"10.4161\/21624011.2014.946365","volume":"3","author":"A Gallois","year":"2014","unstructured":"Gallois A, et al. Reversal of natural killer cell exhaustion by TIM-3 blockade. Oncoimmunology. 2014;3(12):e946365.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2211_CR90","doi-asserted-by":"publisher","first-page":"1889822","DOI":"10.1080\/2162402X.2021.1889822","volume":"10","author":"J Rakova","year":"2021","unstructured":"Rakova J, et al. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. Oncoimmunology. 2021;10(1):1889822.","journal-title":"Oncoimmunology"},{"key":"2211_CR91","doi-asserted-by":"crossref","unstructured":"Koz\u0142owski M, Borzyszkowska D, Cymbaluk-P\u0142oska A. The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer. Biomedicines, 2022. 10(11).","DOI":"10.3390\/biomedicines10112826"},{"issue":"2","key":"2211_CR92","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3233\/CBM-210114","volume":"32","author":"Y Cao","year":"2021","unstructured":"Cao Y, et al. Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy. Cancer Biomark. 2021;32(2):237\u201348.","journal-title":"Cancer Biomark"},{"issue":"13Supplement","key":"2211_CR93","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1158\/1538-7445.AM2019-4148","volume":"79","author":"PG Sasikumar","year":"2019","unstructured":"Sasikumar PG, et al. An orally bioavailable small molecule antagonist of TIM-3 signaling pathway shows potent anti-tumor activity. Cancer Res. 2019;79(13Supplement):4148\u20134148.","journal-title":"Cancer Res"},{"issue":"11","key":"2211_CR94","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"N Sauer","year":"2023","unstructured":"Sauer N, et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother. 2023;72(11):3405\u201325.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"2211_CR95","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.4049\/jimmunol.1300083","volume":"190","author":"SY Lee","year":"2013","unstructured":"Lee SY, Goverman JM. The influence of T cell Ig mucin-3 signaling on central nervous system autoimmune disease is determined by the effector function of the pathogenic T cells. J Immunol. 2013;190(10):4991\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"2211_CR96","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5001\/omj.2014.46","volume":"29","author":"D Haghmorad","year":"2014","unstructured":"Haghmorad D, et al. Calcium intervention ameliorates experimental model of multiple sclerosis. Oman Med J. 2014;29(3):185\u20139.","journal-title":"Oman Med J"},{"issue":"5","key":"2211_CR97","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"key":"2211_CR98","doi-asserted-by":"crossref","unstructured":"Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer, 2022. 10(4).","DOI":"10.1136\/jitc-2022-004711"},{"issue":"3","key":"2211_CR99","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/or.2021.7943","volume":"45","author":"L Liu","year":"2021","unstructured":"Liu L, et al. CD155\/TIGIT, a novel immune checkpoint in human cancers. Oncol Rep. 2021;45(3):835\u201345.","journal-title":"Oncol Rep"},{"issue":"2","key":"2211_CR100","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/08820139.2016.1237524","volume":"46","author":"XG Liu","year":"2017","unstructured":"Liu XG, Hou M, Liu Y. TIGIT: a novel therapeutic target for tumor immunotherapy. Immunol Invest. 2017;46(2):172\u201382.","journal-title":"Immunol Invest"},{"issue":"2","key":"2211_CR101","first-page":"1497","volume":"18","author":"A Hinsch","year":"2019","unstructured":"Hinsch A, et al. Expression of the immune checkpoint receptor TIGIT in seminoma. Oncol Lett. 2019;18(2):1497\u2013502.","journal-title":"Oncol Lett"},{"issue":"1","key":"2211_CR102","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024;12(1):7.","journal-title":"Biomark Res"},{"issue":"2","key":"2211_CR103","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10238-022-00817-0","volume":"23","author":"D Qiu","year":"2023","unstructured":"Qiu D, et al. TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clin Exp Med. 2023;23(2):165\u201374.","journal-title":"Clin Exp Med"},{"key":"2211_CR104","doi-asserted-by":"crossref","unstructured":"Li W et al. The regulatory effects and applications of TIGIT\/CD155 on the tumor microenvironment in HCC. View, 2025: p. 20240071.","DOI":"10.1002\/VIW.20240071"},{"issue":"3","key":"2211_CR105","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8\u2009+\u2009T cell responses. Immunity. 2022;55(3):512\u201326. e9.","journal-title":"Immunity"},{"issue":"1","key":"2211_CR106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10753-024-02045-y","volume":"48","author":"J Ke","year":"2025","unstructured":"Ke J, et al. TIGIT regulates T cell inflammation in airway inflammatory diseases. Inflammation. 2025;48(1):15\u201324.","journal-title":"Inflammation"},{"issue":"14","key":"2211_CR107","doi-asserted-by":"publisher","first-page":"e121157","DOI":"10.1172\/jci.insight.121157","volume":"3","author":"J Fourcade","year":"2018","unstructured":"Fourcade J, et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI insight. 2018;3(14):e121157.","journal-title":"JCI insight"},{"issue":"10","key":"2211_CR108","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.3390\/cancers15102712","volume":"15","author":"MF Hasan","year":"2023","unstructured":"Hasan MF, et al. TIGIT expression on activated NK cells correlates with greater anti-tumor activity but promotes functional decline upon lung cancer exposure: implications for adoptive cell therapy and TIGIT-targeted therapies. Cancers. 2023;15(10):2712.","journal-title":"Cancers"},{"issue":"6","key":"2211_CR109","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21(6):451\u201372.","journal-title":"Cancer Biol Med"},{"issue":"2","key":"2211_CR110","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","volume":"8","author":"A Rousseau","year":"2023","unstructured":"Rousseau A, Parisi C, Barlesi F. Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open. 2023;8(2):101184.","journal-title":"ESMO Open"},{"issue":"1","key":"2211_CR111","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, et al. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22(1):93.","journal-title":"Mol Cancer"},{"key":"2211_CR112","doi-asserted-by":"crossref","unstructured":"Zhang Y et al. Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. in MAbs. 2024. Taylor & Francis.","DOI":"10.1080\/19420862.2024.2419838"},{"issue":"1","key":"2211_CR113","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui H, Hamad M, Elkord E. TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies. Cell Death Dis. 2025;16(1):664.","journal-title":"Cell Death Dis"},{"issue":"9","key":"2211_CR114","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1002\/jcp.30855","volume":"237","author":"M Hemmatzadeh","year":"2022","unstructured":"Hemmatzadeh M, et al. The role of immune regulatory molecules in rheumatoid arthritis: implication for etiopathogenesis and prospective for treatment. J Cell Physiol. 2022;237(9):3541\u201353.","journal-title":"J Cell Physiol"},{"key":"2211_CR115","doi-asserted-by":"publisher","first-page":"1370907","DOI":"10.3389\/fimmu.2024.1370907","volume":"15","author":"P Trivedi","year":"2024","unstructured":"Trivedi P, et al. TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes. Front Immunol. 2024;15:1370907.","journal-title":"Front Immunol"},{"issue":"1","key":"2211_CR116","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","volume":"11","author":"Y Jing","year":"2020","unstructured":"Jing Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11(1):4946.","journal-title":"Nat Commun"},{"issue":"7","key":"2211_CR117","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/2326-6066.CIR-18-0507","volume":"7","author":"J Deng","year":"2019","unstructured":"Deng J, et al. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Cancer Immunol Res. 2019;7(7):1079\u201390.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2211_CR118","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","volume":"74","author":"I Le Mercier","year":"2014","unstructured":"Le Mercier I, et al. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res. 2014;74(7):1933\u201344.","journal-title":"Cancer Res"},{"issue":"41","key":"2211_CR119","doi-asserted-by":"publisher","first-page":"14846","DOI":"10.1073\/pnas.1407447111","volume":"111","author":"L Wang","year":"2014","unstructured":"Wang L, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc Natl Acad Sci U S A. 2014;111(41):14846\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2211_CR120","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1189\/jlb.0209076","volume":"86","author":"A Crawford","year":"2009","unstructured":"Crawford A, Wherry EJ. Editorial: therapeutic potential of targeting BTLA. J Leukoc Biol. 2009;86(1):5\u20138.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2211_CR121","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.imlet.2011.02.003","volume":"138","author":"P Le Bouteiller","year":"2011","unstructured":"Le Bouteiller P, et al. CD160: a unique activating NK cell receptor. Immunol Lett. 2011;138(2):93\u20136.","journal-title":"Immunol Lett"},{"key":"2211_CR122","doi-asserted-by":"publisher","first-page":"113694","DOI":"10.1016\/j.ejmech.2021.113694","volume":"224","author":"M Piotrowska","year":"2021","unstructured":"Piotrowska M, et al. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions. Eur J Med Chem. 2021;224:113694.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2211_CR123","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cmi.2009.108","volume":"7","author":"Z Xu","year":"2010","unstructured":"Xu Z, Jin B. A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell Mol Immunol. 2010;7(1):11\u20139.","journal-title":"Cell Mol Immunol"},{"key":"2211_CR124","doi-asserted-by":"crossref","unstructured":"Krzy\u017canowska N. T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT)\u2014an update on emerging negative immune checkpoints in cancer treatment. Oncology in Clinical Practice; 2025.","DOI":"10.5603\/ocp.102398"},{"issue":"9","key":"2211_CR125","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/bcp.14338","volume":"86","author":"HY Chew","year":"2020","unstructured":"Chew HY, Dolcetti R, Simpson F. Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. Br J Clin Pharmacol. 2020;86(9):1711\u201325.","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"2211_CR126","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.1420370112","volume":"112","author":"J Liu","year":"2015","unstructured":"Liu J, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015;112(21):6682\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2211_CR127","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923\u201337.","journal-title":"Cancer Cell"},{"issue":"10","key":"2211_CR128","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187\u201394.","journal-title":"J Exp Med"},{"issue":"1","key":"2211_CR129","doi-asserted-by":"publisher","first-page":"1708064","DOI":"10.1080\/2162402X.2019.1708064","volume":"9","author":"M Yang","year":"2020","unstructured":"Yang M, et al. Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. Oncoimmunology. 2020;9(1):1708064.","journal-title":"Oncoimmunology"},{"issue":"10","key":"2211_CR130","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-15-3130","volume":"76","author":"T Ahrends","year":"2016","unstructured":"Ahrends T, et al. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4\u2009+\u2009T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res. 2016;76(10):2921\u201331.","journal-title":"Cancer Res"},{"issue":"10","key":"2211_CR131","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-17-3057","volume":"24","author":"SL Buchan","year":"2018","unstructured":"Buchan SL, et al. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8(+) T-Cell-Driven Antitumor Immunity. Clin Cancer Res. 2018;24(10):2383\u201394.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2211_CR132","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","volume":"72","author":"J Fourcade","year":"2012","unstructured":"Fourcade J, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012;72(4):887\u201396.","journal-title":"Cancer Res"},{"issue":"1","key":"2211_CR133","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"2","key":"2211_CR134","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","volume":"33","author":"J Niu","year":"2022","unstructured":"Niu J, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(\u2606). Ann Oncol. 2022;33(2):169\u201380.","journal-title":"Ann Oncol"},{"issue":"15suppl","key":"2211_CR135","doi-asserted-by":"publisher","first-page":"TPS3099","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3099","volume":"35","author":"JJ Lee","year":"2017","unstructured":"Lee JJ, et al. Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas. J Clin Oncol. 2017;35(15suppl):TPS3099\u20133099.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2211_CR136","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","volume":"184","author":"M Dougan","year":"2021","unstructured":"Dougan M, et al. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021;184(6):1575\u201388.","journal-title":"Cell"},{"issue":"6","key":"2211_CR137","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, et al. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol. 2019;40(6):511\u201323.","journal-title":"Trends Immunol"},{"issue":"5","key":"2211_CR138","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40259-018-0303-4","volume":"32","author":"PG Sasikumar","year":"2018","unstructured":"Sasikumar PG, Ramachandra M. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1\/PD-L1 and Other Emerging Checkpoint Pathways. BioDrugs. 2018;32(5):481\u201397.","journal-title":"BioDrugs"},{"issue":"9","key":"2211_CR139","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2211_CR140","doi-asserted-by":"publisher","first-page":"104532","DOI":"10.1016\/j.cellimm.2022.104532","volume":"376","author":"K Wojciechowicz","year":"2022","unstructured":"Wojciechowicz K, et al. The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases. Cell Immunol. 2022;376:104532.","journal-title":"Cell Immunol"},{"issue":"1","key":"2211_CR141","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1107753","volume":"86","author":"W Truong","year":"2009","unstructured":"Truong W, et al. BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol. 2009;86(1):41\u201351.","journal-title":"J Leukoc Biol"},{"issue":"12","key":"2211_CR142","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.4049\/jimmunol.1501973","volume":"196","author":"E Huarte","year":"2016","unstructured":"Huarte E, et al. Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis. J Immunol. 2016;196(12):5036\u201346.","journal-title":"J Immunol"},{"issue":"5","key":"2211_CR143","doi-asserted-by":"publisher","first-page":"e0155345","DOI":"10.1371\/journal.pone.0155345","volume":"11","author":"B Yang","year":"2016","unstructured":"Yang B, et al. The Expression of BTLA Was Increased and the Expression of HVEM and LIGHT Were Decreased in the T Cells of Patients with Rheumatoid Arthritis [corrected]. PLoS ONE. 2016;11(5):e0155345.","journal-title":"PLoS ONE"},{"issue":"2","key":"2211_CR144","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/09540105.2013.878900","volume":"26","author":"SZT Rabe","year":"2015","unstructured":"Rabe SZT, et al. Inhibitory effect of Crocus sativus L. ethanol extract on adjuvant-induced arthritis. Food Agricultural Immunol. 2015;26(2):170\u201380.","journal-title":"Food Agricultural Immunol"},{"issue":"2","key":"2211_CR145","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1365-2567.2004.02004.x","volume":"114","author":"WJ Kim","year":"2005","unstructured":"Kim WJ, et al. LIGHT is involved in the pathogenesis of rheumatoid arthritis by inducing the expression of pro-inflammatory cytokines and MMP-9 in macrophages. Immunology. 2005;114(2):272\u20139.","journal-title":"Immunology"},{"key":"2211_CR146","doi-asserted-by":"publisher","first-page":"29699","DOI":"10.1038\/srep29699","volume":"6","author":"F Piancone","year":"2016","unstructured":"Piancone F, et al. B Lymphocytes in Multiple Sclerosis: Bregs and BTLA\/CD272 Expressing-CD19\u2009+\u2009Lymphocytes Modulate Disease Severity. Sci Rep. 2016;6:29699.","journal-title":"Sci Rep"},{"issue":"11","key":"2211_CR147","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1177\/1352458520977045","volume":"27","author":"MA Tapia-Maltos","year":"2021","unstructured":"Tapia-Maltos MA, et al. Identification of regulatory T cell molecules associated with severity of multiple sclerosis. Mult Scler. 2021;27(11):1695\u2013705.","journal-title":"Mult Scler"},{"issue":"7","key":"2211_CR148","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.4049\/jimmunol.180.7.4409","volume":"180","author":"L Yang","year":"2008","unstructured":"Yang L, et al. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol. 2008;180(7):4409\u201314.","journal-title":"J Immunol"},{"key":"2211_CR149","doi-asserted-by":"publisher","first-page":"667991","DOI":"10.3389\/fimmu.2021.667991","volume":"12","author":"A Wiedemann","year":"2021","unstructured":"Wiedemann A, et al. BTLA Expression and Function Are Impaired on SLE B Cells. Front Immunol. 2021;12:667991.","journal-title":"Front Immunol"},{"issue":"8","key":"2211_CR150","first-page":"936","volume":"16","author":"M Rastin","year":"2013","unstructured":"Rastin M, et al. T lymphocyte apoptosis in systemic lupus erythematosus patients. Iran J Basic Med Sci. 2013;16(8):936\u201341.","journal-title":"Iran J Basic Med Sci"},{"key":"2211_CR151","doi-asserted-by":"crossref","unstructured":"Sawaf M et al. Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4\u2009+\u2009T cells. JCI Insight, 2018. 3(13).","DOI":"10.1172\/jci.insight.99711"},{"issue":"4","key":"2211_CR152","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4049\/jimmunol.1900823","volume":"204","author":"M Angin","year":"2020","unstructured":"Angin M, Brignone C, Triebel F. A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases. J Immunol. 2020;204(4):810\u20138.","journal-title":"J Immunol"},{"key":"2211_CR153","doi-asserted-by":"crossref","unstructured":"Du W et al. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. Int J Mol Sci, 2017. 18(3).","DOI":"10.3390\/ijms18030645"},{"issue":"24","key":"2211_CR154","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.3390\/cancers15245841","volume":"15","author":"J Ahmed","year":"2023","unstructured":"Ahmed J, et al. Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies. Cancers. 2023;15(24):5841.","journal-title":"Cancers"},{"key":"2211_CR155","doi-asserted-by":"publisher","first-page":"694055","DOI":"10.3389\/fimmu.2021.694055","volume":"12","author":"B Shibru","year":"2021","unstructured":"Shibru B, et al. Detection of immune checkpoint receptors\u2013a current challenge in clinical flow cytometry. Front Immunol. 2021;12:694055.","journal-title":"Front Immunol"},{"issue":"2","key":"2211_CR156","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3109\/08923970903338367","volume":"32","author":"G Mosayebi","year":"2010","unstructured":"Mosayebi G, et al. Therapeutic effect of EDTA in experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol. 2010;32(2):321\u20136.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"5","key":"2211_CR157","doi-asserted-by":"publisher","first-page":"e70345","DOI":"10.1002\/ctm2.70345","volume":"15","author":"S Xiang","year":"2025","unstructured":"Xiang S, Li S, Xu J. Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy. Clin Translational Med. 2025;15(5):e70345.","journal-title":"Clin Translational Med"},{"key":"2211_CR158","doi-asserted-by":"publisher","first-page":"1078338","DOI":"10.3389\/fphar.2023.1078338","volume":"14","author":"W Liu","year":"2023","unstructured":"Liu W, et al. Current landscape and tailored management of immune-related adverse events. Front Pharmacol. 2023;14:1078338.","journal-title":"Front Pharmacol"},{"issue":"11","key":"2211_CR159","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11912-021-01124-9","volume":"23","author":"A De Giglio","year":"2021","unstructured":"De Giglio A, et al. The landscape of immunotherapy in advanced NSCLC: driving beyond PD-1\/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines). Curr Oncol Rep. 2021;23(11):126.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2211_CR160","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"5","key":"2211_CR161","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/cancers15051629","volume":"15","author":"I Les","year":"2023","unstructured":"Les I, et al. Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers. 2023;15(5):1629.","journal-title":"Cancers"},{"key":"2211_CR162","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","volume":"11","author":"Y Xu","year":"2020","unstructured":"Xu Y, et al. Predictive biomarkers of immune checkpoint inhibitors-related toxicities. Front Immunol. 2020;11:2023.","journal-title":"Front Immunol"},{"issue":"9","key":"2211_CR163","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/v12091051","volume":"12","author":"H Cai","year":"2020","unstructured":"Cai H, et al. Immune checkpoints in viral infections. Viruses. 2020;12(9):1051.","journal-title":"Viruses"},{"issue":"10","key":"2211_CR164","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/biology12101358","volume":"12","author":"A Del Bello","year":"2023","unstructured":"Del Bello A, Treiner E. Immune checkpoints in solid organ transplantation. Biology. 2023;12(10):1358.","journal-title":"Biology"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02211-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:04:25Z","timestamp":1773792265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":164,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2211"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02211-y","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"58"}}